Rosiglitazone potassium

Synonyms: BRL 49653 potassium
Rosiglitazone (BRL 49653) potassium 是一种具有口服活性的 PPARγ 选择性激动剂(EC50: 60 nM,Kd: 40 nM),同时也是 TRPC5 激活剂(EC50: 30 μM)和 TRPM3 抑制剂,可用于肥胖、糖尿病、衰老及卵巢癌的研究。
产品编号: MS-X68395 纯度: 99.13% CAS No.: 316371-84-3 分子式: C18H18KN3O3S 分子量: 395.52
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Rosiglitazone (BRL 49653) potassium 是一种具有口服活性的 PPARγ 选择性激动剂(EC50: 60 nM,Kd: 40 nM),同时也是 TRPC5 激活剂(EC50: 30 μM)和 TRPM3 抑制剂,可用于肥胖、糖尿病、衰老及卵巢癌的研究。

生物实验数据

生物活性 Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM) that also acts as a TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor, and can be used for research on obesity, diabetes, aging, and ovarian cancer.
IC50 & Target PPARγ:60 nM (EC50), TRPC5:30 μM (EC50), PPARγ:40 nM (Kd)
体外研究
(In Vitro)

Rosiglitazone potassium (0.1-10 μM, 72 h) results in pluripotent C3H10T1/2 stem cell differentiation to adipocytes.
Rosiglitazone potassium (1 μM, 24 h) activates PPARγ, which binds to NF-α1 promoter to activate gene transcription in neurons.
Rosiglitazone potassium (1 μM, 24 h) protects Neuro2A cells and hippocampal neurons against oxidative stress, and up-regulates BCL-2 expression in an NF-α1-dependent manner.
Rosiglitazone potassium (0.01-100 μM, 15 min) inhibits TRPM3 with IC50 values of 9.5 and 4.6 μM against nifedipine- and PregS-evoked activity respectively.
Rosiglitazone potassium (0.5-50 μM, 7 days) inhibits ovarian cancer cell proliferation.
Rosiglitazone potassium (5 μM, 7 days) suppresses Olaparib (MS-Y92542) induced alterations of cellular senescence and promotes apoptosis in A2780 and SKOV3 cells.

Cell Proliferation Assay

Cell Line: A2780 and SKOV3 cells
Concentration: 0.5-50 μM
Incubation Time: 1-7 days
Result: Inhibited cell proliferation in a time‑dependent and concentration‑dependent manner.

Western Blot Analysis

Cell Line: Hippocampal neurons
Concentration: 1 μM
Incubation Time: 24 h
Result: Increased NF-α1 and BCL-2 protein level.
体内研究
(In Vivo)

Rosiglitazone potassium (oral administration, 5 mg/kg, daily for 8 weeks) decreases the serum glucose in diabetic rats.
Rosiglitazone potassium (intraperitoneal injection, 3 mg/kg/day) ameliorates airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα in male Wistar rats.
Rosiglitazone potassium (intraperitoneal injection, 10 mg/kg, once every 2 days) inhibits subcutaneous ovarian cancer growth in A2780 and SKOV3 mouse subcutaneous xenograft models.

Animal Model: Streptozotocin (STZ)-induced diabetic rats
Dosage: 5 mg/kg
Administration: Oral administration, daily for 8 weeks.
Result: Decreased IL-6, TNF-α, and VCAM-1 levels in diabetic group.
Displayed lower levels of lipid peroxidation and NOx with an increase in aortic GSH and SOD levels compared to diabetic groups.
Animal Model: Male Wistar rats
Dosage: 3 mg/kg/day
Administration: Intraperitoneal injection, twice a day, 6 days per week for 12 consecutive weeks
Result: Ameliorated emphysema, elevated PEF, and higher level of total cells, neutrophils and cytokines (TNF-α and IL-1β) induced by cigarette smoke (CS).
Inhibited CS-induced M1 macrophage polarization and decreased the ratio of M1/M2.
性状 固体
颜色 White to off-white

化学信息

分子量 395.52
分子式 C18H18KN3O3S
CAS No. 316371-84-3
别名 BRL 49653 potassium

储存&溶解度

储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础